Rating Rationale
October 04, 2022 | Mumbai
Nidan Laboratories and Healthcare Limited
Rating migrated to 'CRISIL BB / Stable'
 
Rating Action
Total Bank Loan Facilities RatedRs.15 Crore
Long Term Rating&CRISIL BB/Stable (Migrated from 'CRISIL B+ / Stable ISSUER NOT COOPERATING*')
& *Issuer did not cooperate; based on best-available information
Note: None of the Directors on CRISIL Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

Due to inadequate information, CRISIL, in line with SEBI guidelines, had migrated the rating of Nidan Laboratories and Healthcare Limited (Nidan) to CRISIL B+/Stable; Issuer Not Cooperating'. However, the management has subsequently started sharing requisite information, necessary for carrying out comprehensive review of the rating.  Consequently, CRISIL is migrating the rating on bank facilities of Nidan from 'CRISIL B+/Stable;  Issuer Not Cooperating' to 'CRISIL BB/Stable'.

 

The rating reflects the extensive experience of  promoters in the diagnostics industry, healthy operating margin and above average financial risk profile. This strength is partially offset by the  modest scale of operations, exposure to intense competition and working capital intensive operations.  

Analytical Approach

Unsecured loans of Rs 2.18 crores as on March 31, 2022 has been treated as debt.

Key Rating Drivers & Detailed Description

Strengths:

Established track record in diagnostics industry:

Nidan was started in 2000 by Dr, Nitin Thorve. Dr Nidan Thorve has an established track record of over 16 years in the diagnostic industry. Over the years, the company has increased the number of diagnostic centers to 35 from around 15 in 2015 and presently offers about 400 services across different specialties, including urology, cardiology, orthopedic, neurology, ophthalmology, and others and revenues have grown to Rs 30 crores in Fiscal 2022 from Rs 22 crores in Fiscal 2020.  

 

Healthy operating margins

Operating margins have been healthy in the range of 35-40% in the last 4 fiscals and expected to remain in similar range over the medium term.

 

Above-average financial risk profile

Financial risk profile has been healthy for the company as reflected through gearing and total outside liabilities to adjusted net worth of 0.29 times and 0.34 times, respectively, as on March 31, 2022. Debt protection metrics have been comfortable with interest coverage of 3.10 times and net cash accruals to adjusted debt of 0.27 times for fiscal 2022. With the expected increase in scale of operations and healthy accretion to reserves, financial risk profile is expected to remain healthy over the medium term.

 

Weakness:

Modest scale of operations and exposure to intense competition in industry:

In spite of being in the business since last 17 years, Nidan has modest scale of operations as reflected in revenues of around Rs 30 crores in Fiscal 2022. It is exposed to intense competition with many competing diagnostic centres in each of the areas it operates in. Moreover, it faces competition from hospitals which are equipped with in-house diagnostic facilities.

 

Exposure to risk relating to geographic concentration in revenue profile:

Nidans operations are limited to Mumbai and Pune with customers in and around Mumbai and Pune. The geographical concentration of the firm renders it vulnerable to the dynamics of single market. Furthermore the image sensitive nature of the diagnostic centre industry further aggravates the risks relating to geographic concentration of the firms revenue profile.

 

 Working Capital intensive operations 

Operations have been working capital intensive for the company as reflected in Gross current asset days of 298 days as on March 31, 2022. It was majorly driven by debtor days of 66 days and inventory days of 4 days . Operations are expected to remain working capital intensive in the future.

Liquidity: Adequate

Cash accruals are expected to be around Rs 8-9 crores against repayment obligations of Rs 1.16 crores and Rs 1.81 crores in fiscals 2023 and 2024, respectively. Bank limit utilization has been around 97% for the last 12 months ended June 2022. Current ratio is moderate at 1.90 times as on March 31, 2022. Cash and bank balance stood at Rs 8.10 crores as on March 31, 2022.

Outlook Stable

CRISIL Ratings believes Nidan will continue to benefit over the medium term from promoters' extensive experience in the diagnostic center’s experience  

Rating Sensitivity factors

Upward factors

  • Sustained improvement in scale of operation and sustenance of operating margin, leading to higher cash accruals.
  • Sustenance of financial risk profile and improvement in working capital cycle leading to nank limit utilization below 90%

 

Downward Factors

  • Decline in revenue or operating margin, leading to cash accruals below Rs 4 crores
  • Debt funded capex or higher investment in join venture, weakens capital structure

About the Company

Nidan was established in 2000 by Dr. Nitin Thorve and Mrs. Roshan Thorve  The company runs 35 diagnostic centres across greater Mumbai. Nidan operates its centres through the brand named 'Nidan Diagnostics and offers services including CT scan, MRI, Ultra Sound, 2D Echo, ECG, etc. The company is listed on NSE

Key Financial Indicators

As on / for the period ended March 31

 

2022

2021

Operating income

Rs crore

29.77

21.85

Reported profit after tax

Rs crore

2.46

2.30

PAT margins

%

8.95

10.54

Adjusted Debt/Adjusted Net worth

Times

0.26

2.32

Interest coverage

Times

3.01

2.87

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

CRISIL Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the CRISIL Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of Instrument

Date of Allotment

Coupon Rate (%)

Maturity Date

Issue Size (Rs Crore)

Complexity Level

Rating Assigned with Outlook

NA

Cash Credit

NA

NA

NA

8.8

NA

CRISIL BB/Stable

NA

Term Loan

NA

NA

31-Mar-24

4.82

NA

CRISIL BB/Stable

NA

Working Capital Term Loan

NA

NA

31-Mar-24

1.38

NA

CRISIL BB/Stable

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 15.0 CRISIL BB/Stable 17-02-22 CRISIL B+ /Stable(Issuer Not Cooperating)*   -- 09-12-20 CRISIL B+ /Stable(Issuer Not Cooperating)* 05-09-19 CRISIL B+ /Stable(Issuer Not Cooperating)* CRISIL BB- /Stable(Issuer Not Cooperating)*
All amounts are in Rs.Cr.
* - Issuer did not cooperate; based on best-available information
 
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Cash Credit 8.8 Corporation Bank CRISIL BB/Stable
Term Loan 4.82 Corporation Bank CRISIL BB/Stable
Working Capital Term Loan 1.38 Corporation Bank CRISIL BB/Stable

This Annexure has been updated on 08-Mar-2023 in line with the lender-wise facility details as on 23-Feb-2023 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Assessing Information Adequacy Risk
Rating Criteria for Fast Moving Consumer Goods Industry
CRISILs Criteria for rating short term debt

Media Relations
Analytical Contacts
Customer Service Helpdesk

Aveek Datta
Media Relations
CRISIL Limited
M: +91 99204 93912
B: +91 22 3342 3000
AVEEK.DATTA@crisil.com

Prakruti Jani
Media Relations
CRISIL Limited
M: +91 98678 68976
B: +91 22 3342 3000
PRAKRUTI.JANI@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Ankita Gupta
Associate Director
CRISIL Ratings Limited
D:+91 22 4097 8104
ankita.gupta@crisil.com


Himanshu Khare
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Himanshu.Khare@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited, an S&P Global Company)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a leading, agile and innovative global analytics company driven by its mission of making markets function better. 

It is India’s foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee - more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html